Literature DB >> 14976605

Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11.

Andrea Vambutas1, Vincent R Bonagura, Elaine F Reed, Allan L Abramson, Virginia Mullooly, James DeVoti, David W Gjertson, Bettie M Steinberg.   

Abstract

Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomaviruses (HPVs). It is characterized by multiple recurrences of benign neoplasms and has a variable clinical course, ranging from infrequent recurrence to acute airway obstruction. One way in which HPV subverts the immune system in RRP is by interfering with TAP1 (transporter associated with antigen presentation 1). We examined whether a known TAP1 polymorphism in the ATPase domain altered the severity of disease in patients with RRP. The presence of this polymorphism was significantly correlated with severity of disease (P=.015). Because of the proximity of the TAP1 gene to human leukocyte antigen (HLA) class II genes on chromosome 6, we postulated that a linkage disequilibrium may exist. Of the patients with polymorphic TAP1, 36% were positive for HLA-DRB1*0102 (P=.021; P=.147 with Bonferroni's correction). However, this association appeared to mitigate the severity of disease (P=.04). Therefore, severity of disease in a patient with RRP might be determined by sequencing TAP1, in conjunction with HLA class II genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976605     DOI: 10.1086/381764

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

2.  Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression.

Authors:  Corina Heller; Tanja Weisser; Antje Mueller-Schickert; Elke Rufer; Alexander Hoh; Ralf M Leonhardt; Michael R Knittler
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 3.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

4.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

5.  Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis.

Authors:  James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

Review 6.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

Review 7.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

8.  Association between the TAP1 gene polymorphisms and recurrent respiratory papillomatosis in patients from Western Mexico: A pilot study.

Authors:  Jaime Palomares-Marin; Luis Humberto Govea-Camacho; Vania Araujo-Caballero; Gerardo Cazarez-Navarro; Sergio Yair Rodriguez-Preciado; Enrique Ortiz-Hernandez; Erika Martinez-Lopez; Jose Francisco Muñoz-Valle; Ivan Isidro Hernandez-Cañaveral
Journal:  J Clin Lab Anal       Date:  2021-01-28       Impact factor: 2.352

Review 9.  Biologics for the Treatment of Recurrent Respiratory Papillomatosis.

Authors:  Clint T Allen
Journal:  Otolaryngol Clin North Am       Date:  2021-06-05       Impact factor: 1.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.